Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

https://www.soho2019.com/

 

Phase 1 CML-041 Results on Combination of Asciminib, a Novel and Specific BCRABL1 Inhibitor, Plus Imatinib in Previously Treated CML

November 18, 2019

0 Comments
Login to view comments. Click here to Login